Patient-reported outcome measures should not be the primary outcome in glaucoma clinical trials of disease modification-Reference-Cited by-同舟云学术

Patient-reported outcome measures should not be the primary outcome in glaucoma clinical trials of disease modification

Published:2022-07-05 Issue:1 Volume:107 Page:3-5
ISSN:0007-1161
Container-title:British Journal of Ophthalmology
language:en
Short-container-title:Br J Ophthalmol

Author:

Rabiolo Alessandro^ORCID,Barton Keith,McNaught Andrew Ian

Publisher

BMJ

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Reference33 articles.

1. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

2. Surrogate Endpoint Resources for Drug and Biologic Development . Secondary surrogate endpoint resources for drug and biologic development 2018. Available: https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development

3. Biomarkers and surrogate endpoints in glaucoma clinical trials

4. Biomarkers and surrogate endpoints: lessons learned from glaucoma;Medeiros;Invest Ophthalmol Vis Sci,2017

5. Association between progressive retinal nerve fiber layer loss and longitudinal change in quality of life in glaucoma;Gracitelli;JAMA Ophthalmol,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypotony Failure Criteria in Glaucoma Surgical Studies and Their Influence on Surgery Success;Ophthalmology;2024-07

2. Evaluating Primary Treatment for People with Advanced Glaucoma;Ophthalmology;2024-07

3. Priorities for health outcomes in glaucoma in an ethnically diverse UK cohort: an observational study;BMJ Open;2024-05

4. European Glaucoma Society – A guide on surgical innovation for glaucoma;British Journal of Ophthalmology;2023-12

5. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment;The Ocular Surface;2023-07